{"disease":{"id":"squamous-cell-carcinoma-of-larynx","name":"Squamous cell carcinoma of larynx","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cetuximab","indication_name":"Squamous cell carcinoma of larynx","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Erbitux","generic_name":"cetuximab","company_name":"Imclone","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"Epidermal Growth Factor Receptor Antagonist [EPC]","quality_score":62,"revenue":null,"mechanism":"Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division."},{"drug_id":"erbitux","indication_name":"Squamous cell carcinoma of larynx","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Erbitux","company_name":"Hellenic Oncology Research Group","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01473784","title":"Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06947668","title":"Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT02245100","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT01064479","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03370276","title":"Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT01469429","title":"Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01847326","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT00494182","title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04943445","title":"Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05992610","title":"Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Maria Sklodowska-Curie National Research Institute of Oncology","has_results":false},{"nct_id":"NCT07063212","title":"A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05144698","title":"RAPA-201 Therapy of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"Rapa Therapeutics LLC","has_results":false},{"nct_id":"NCT05752149","title":"Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":27,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT02048020","title":"Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01316757","title":"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT02113878","title":"Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT03381183","title":"IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT00470496","title":"Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT02464137","title":"HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03114462","title":"Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":11,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02177838","title":"Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT02035527","title":"Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05608369","title":"Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}